THE FDA GRANTED ACCELERATED APPROVAL TO ZANUBRUTINIB FOR CERTAIN ADULTS WITH MARGINAL ZONE LYMPHOMA The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa) for certain adult patients with marginal zone...
9/11 first responders’ cancer survival compares favorably to the general population, and more news of the week from Cancer Today.
Cancer is often described as a disease of old age, but over 15,000 children are diagnosed with cancer each year in the United States. While pediatric cancers tend to have higher survival rates than...
High-poverty counties in the United States may lag far behind wealthier counties in eliminating cervical cancer, a study published in the AACR journal Cancer Epidemiology, Biomarkers & Prevention found.
Researchers investigate how antibiotics might increase the risk of colon cancer, and other news of the week selected by the staff of Cancer Today magazine.
A drug that delivers radioactive particles to prostate cancer cells increases overall survival for metastatic castration-resistant prostate cancer.
What if a machine could “think” like a doctor and diagnose and treat a disease? This is one of the long-term goals for the field of artificial intelligence (AI). In a session co-sponsored by the American Association for Cancer Research...
The FDA approved zanubrutinib, a tyrosine kinase inhibitor, for this form of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa) for adult patients with Waldenström macroglobulinemia, a slow-growing form of...
Regular exercise can help mitigate cognitive problems associated with chemotherapy, and more news of the week from Cancer Today.
The U.S. FDA approved a molecularly targeted therapeutic to treat certain patients with cholangiocarcinoma. The U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic ivosidenib (Tibsovo) for certain patients with cholangiocarcinoma—bile duct...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now